<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560715</url>
  </required_header>
  <id_info>
    <org_study_id>Rubens Siqueira</org_study_id>
    <nct_id>NCT01560715</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa</brief_title>
  <acronym>RETICELL</acronym>
  <official_title>Phase 2 Study Of Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the short-term safety and efficacy of a single
      intravitreal injection of autologous bone marrow stem cells in patients with retinitis
      pigmentosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective phase II, nonrandomized open-label study of retinitis pigmentosa patients with
      best-corrected ETDRS visual acuity (BCVA) worse than 20/200. Standardized ophthalmic
      evaluation will be perform at baseline and at weeks 1, 4,12 and 24 (Â±1) following
      intravitreal injection of 10 x 106 bone marrow stem cells/ 0,1ml . Three measures will be
      used to evaluate the short-term safety of intravitreal of ABMDSC: 1) severe visual loss,
      defined as a drop in 15 letters on ETDRS visual acuity scale; 2) decrease in ERG response; 3)
      decrease in 5 square degrees on visual field; secondary safety outcomes : 1) increase in
      intra-ocular inflammation defined herein as anterior chamber cells and flare higher than 3+
      for more than 1 month after injection according to a classification described elsewhere ; 2)
      decrease in CMT more than 50um; 3)genesis of abnormal tissues (teratomas) or tumors; 4)
      qualitative changes in retinal or choroidal perfusion, like macular nonperfusion. Secondary
      outcome measures will be used to evaluate the short-term efficiency of intravitreal of
      ABMDSC: 1) improvement in ERG response; 2) increase in visual field: 3) increase in CSMT &gt;
      50um and not related to macular edema; 4) increase &gt; 5 letters on BCVA
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ETDRS Visual acuity change</measure>
    <time_frame>Day 1 to Day 365</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Experimental: Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200 or visual field less than 20 degrees</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intravitreal injection of autologous bone marrow stem cells</intervention_name>
    <description>One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.</description>
    <arm_group_label>Experimental: Test group</arm_group_label>
    <other_name>autologous bone marrow stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of retinitis pigmentosa logarithm of minimum angle of resolution (logMAR)
             BCVA of 1.0 (Snellen equivalent, 20/200) or worse

          -  visual Field less than 20 degreees

        Exclusion Criteria:

          -  previous ocular surgery other than cataract

          -  presence of cataract or other media opacity that would influence ocular fundus
             documentation and adequate ERG and visual field evaluation

          -  other ophthalmic disease like glaucoma and uveitis

          -  previous history of blood disorders like leukemia

          -  known allergy to fluorescein or indocyanine green

          -  known coagulation abnormalities or current use of anticoagulative medication other
             than aspirin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubens C Siqueira, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sao Paulo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Pesquisa Rubens Siqueira</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15010-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R. Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial. Retina. 2011 Jun;31(6):1207-14. doi: 10.1097/IAE.0b013e3181f9c242.</citation>
    <PMID>21293313</PMID>
  </reference>
  <reference>
    <citation>Siqueira RC, Messias A, Messias K, Arcieri RS, Ruiz MA, Souza NF, Martins LC, Jorge R. Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells (Reticell -clinical trial). Stem Cell Res Ther. 2015 Mar 14;6:29. doi: 10.1186/s13287-015-0020-6.</citation>
    <PMID>25890251</PMID>
  </reference>
  <reference>
    <citation>Siqueira RC. Stem cell therapy in retinal diseases? Rev Bras Hematol Hemoter. 2012;34(3):222-6. doi: 10.5581/1516-8484.20120054.</citation>
    <PMID>23049424</PMID>
  </reference>
  <reference>
    <citation>Siqueira RC, Messias A, Voltarelli JC, Messias K, Arcieri RS, Jorge R. Resolution of macular oedema associated with retinitis pigmentosa after intravitreal use of autologous BM-derived hematopoietic stem cell transplantation. Bone Marrow Transplant. 2013 Apr;48(4):612-3. doi: 10.1038/bmt.2012.185. Epub 2012 Sep 24.</citation>
    <PMID>23000646</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Rubens Camargo Siqueira</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Retinitis pigmentosa</keyword>
  <keyword>stem cell</keyword>
  <keyword>bone marrow</keyword>
  <keyword>retinal dysprophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

